Disruptive, drug free treatment of knee osteoarthritis using novel materials and...
Disruptive, drug free treatment of knee osteoarthritis using novel materials and minimally invasive catheter delivery
EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5 years. The solution involves em...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PID2019-110709RB-I00
DESARROLLO DE MICROCAPSULAS BIOADHESIVAS PARA NUEVOS TRATAMI...
254K€
Cerrado
AL U KNEED
First in class lateral meniscus prothesis to relieve pain an...
4M€
Cerrado
VitaDisc
A novel non-invasive therapy based on injectable viscous gel...
5M€
Cerrado
ANCHOR
Articular cartilage regeneration through the recruitment of...
150K€
Cerrado
JointPrinting
3D Printing of Cell Laden Biomimetic Materials and Biomolecu...
2M€
Cerrado
ReCaP
Regeneration of Articular Cartilage using Advanced Biomateri...
3M€
Cerrado
Información proyecto EmboSure
Duración del proyecto: 27 meses
Fecha Inicio: 2022-04-04
Fecha Fin: 2024-07-31
Líder del proyecto
CRANNMED LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
EmboSure is a breakthrough treatment for Knee Osteoarthritis. It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5 years. The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed. The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period. This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body. The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee. As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.